Tevogen Bio's (TVGN) Buy Rating Reaffirmed at D. Boral Capital

Tevogen Bio (NASDAQ:TVGN - Get Free Report)'s stock had its "buy" rating reiterated by equities research analysts at D. Boral Capital in a research report issued on Monday,Benzinga reports. They presently have a $10.00 target price on the stock.

Tevogen Bio Trading Down 1.7%

TVGN stock traded down $0.02 during trading on Monday, hitting $1.13. 258,764 shares of the company traded hands, compared to its average volume of 5,019,804. Tevogen Bio has a 1 year low of $0.26 and a 1 year high of $3.09. The company has a 50-day moving average of $1.07 and a 200-day moving average of $1.25.

Insider Activity at Tevogen Bio

In other Tevogen Bio news, insider Neal Flomenberg sold 88,519 shares of the stock in a transaction that occurred on Thursday, March 6th. The stock was sold at an average price of $1.10, for a total value of $97,370.90. Following the completion of the sale, the insider now owns 4,040,485 shares in the company, valued at approximately $4,444,533.50. This trade represents a 2.14% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Insiders sold 406,510 shares of company stock worth $446,763 in the last ninety days. 73.24% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the company. Nuveen LLC bought a new position in shares of Tevogen Bio in the 1st quarter worth approximately $97,000. Northern Trust Corp grew its holdings in shares of Tevogen Bio by 13.0% in the fourth quarter. Northern Trust Corp now owns 118,415 shares of the company's stock worth $122,000 after acquiring an additional 13,595 shares during the period. XTX Topco Ltd purchased a new position in Tevogen Bio during the fourth quarter valued at $55,000. Barclays PLC lifted its position in Tevogen Bio by 39.2% during the fourth quarter. Barclays PLC now owns 45,600 shares of the company's stock valued at $48,000 after purchasing an additional 12,847 shares in the last quarter. Finally, Geode Capital Management LLC lifted its position in Tevogen Bio by 31.2% during the fourth quarter. Geode Capital Management LLC now owns 451,851 shares of the company's stock valued at $465,000 after purchasing an additional 107,566 shares in the last quarter.

About Tevogen Bio

Tevogen Bio Holdings Inc operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients.